Deutsche Bank Comments on Victrelis FDA Approval

FDA approval came on May 13 and Merck & Co. Inc. MRK will launch Victrelis this month, Deutsche Bank reports. “Labeling was generally very favorable for boceprevir, with no major exclusions or restrictions (other than for DDIs), and potential RGT options for most patients -- in our view, about as good a label as MRK could have to work with, based on the data,” Deutsche Bank writes. “Our outlook for boceprevir remains unchanged, with forecasted WW sales of $875 million in 2015.” Merck closed Friday at $37.08.